180 related articles for article (PubMed ID: 25168621)
1. Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.
van Maarseveen EM; Bouma A; Touw DJ; Neef C; van Zanten AR
Eur J Clin Pharmacol; 2014 Nov; 70(11):1353-9. PubMed ID: 25168621
[TBL] [Abstract][Full Text] [Related]
2. Switching From Intermittent to Continuous Infusion of Vancomycin in Critically Ill Patients: Toward a More Robust Exposure.
van Maarseveen EM; Gipmans S; Vasbinder E; Petjak M; van Zanten AR
Ther Drug Monit; 2016 Jun; 38(3):398-401. PubMed ID: 26926670
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
4. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
Frazee E; Rule AD; Lieske JC; Kashani KB; Barreto JN; Virk A; Kuper PJ; Dierkhising RA; Leung N
Am J Kidney Dis; 2017 May; 69(5):658-666. PubMed ID: 28131530
[TBL] [Abstract][Full Text] [Related]
5. Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients.
Colin PJ; Jonckheere S; Struys MMRF
Clin Pharmacokinet; 2018 Nov; 57(11):1435-1447. PubMed ID: 29512049
[TBL] [Abstract][Full Text] [Related]
6. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an empiric vancomycin dosing algorithm for improved target concentration attainment in patients with thermal injury.
Hill DM; Velamuri SR; Lanfranco J; Romero Legro I; Sinclair SE; Hickerson WL
Burns; 2019 Mar; 45(2):423-432. PubMed ID: 30340863
[TBL] [Abstract][Full Text] [Related]
8. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
[TBL] [Abstract][Full Text] [Related]
9. Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology-oncology: prospective validation of a dosing regimen optimizing steady-state concentration.
Hoegy D; Goutelle S; Garnier N; Rénard C; Faure-Conter C; Bergeron C; Bertrand Y; Bleyzac N
Fundam Clin Pharmacol; 2018 Jun; 32(3):323-329. PubMed ID: 29315849
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Continuous Infusion Vancomycin Administration in a Critically Ill Trauma Population.
Bissell BD; Riggi G; Morrison C
J Intensive Care Med; 2020 Jun; 35(6):570-575. PubMed ID: 29642744
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients.
Saugel B; Gramm C; Wagner JY; Messer M; Lahmer T; Meidert AS; Schmid RM; Huber W
J Crit Care; 2014 Jun; 29(3):351-5. PubMed ID: 24456810
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion.
Byl B; Jacobs F; Wallemacq P; Rossi C; de Francquen P; Cappello M; Leal T; Thys JP
Antimicrob Agents Chemother; 2003 Jun; 47(6):2015-7. PubMed ID: 12760889
[TBL] [Abstract][Full Text] [Related]
13. Exposure Variability and Target Attainment of Vancomycin: A Systematic Review Comparing Intermittent and Continuous Infusion.
van Maarseveen EM; Gipmans SGH; van Zanten ARH
Ther Drug Monit; 2020 Jun; 42(3):381-391. PubMed ID: 32432845
[TBL] [Abstract][Full Text] [Related]
14. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.
Blot S; Koulenti D; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J; Roberts JA
Crit Care; 2014 May; 18(3):R99. PubMed ID: 24887569
[TBL] [Abstract][Full Text] [Related]
15. Validation of Vancomycin Dosing Guidance During Transition of Care.
Ng TM; Heng ST; Oon J; Chan M; Tam VH
J Clin Pharmacol; 2021 Jun; 61(6):806-809. PubMed ID: 33258161
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients.
Hong LT; Goolsby TA; Sherman DS; Mueller SW; Reynolds P; Cava L; Neumann R; Kiser TH
J Crit Care; 2015 Oct; 30(5):1153.e1-6. PubMed ID: 26239323
[TBL] [Abstract][Full Text] [Related]
17. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.
Elbarbry F
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):259-268. PubMed ID: 29260505
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
